Home » Stocks » ARAV

Aravive, Inc. (ARAV)

Stock Price: $5.15 USD 0.31 (6.40%)
Updated May 18, 2021 1:13 PM EDT - Market open
Market Cap 98.68M
Revenue (ttm) 5.94M
Net Income (ttm) -27.75M
Shares Out 18.07M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $5.15
Previous Close $4.84
Change ($) 0.31
Change (%) 6.40%
Day's Open 4.86
Day's Range 4.81 - 5.24
Day's Volume 82,667
52-Week Range 4.27 - 14.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer

3 weeks ago - GlobeNewsWire

HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b tri...

2 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, AKBA, BGNE, IMO, IOVA ...
2 months ago - 24/7 Wall Street

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities p...

3 months ago - GlobeNewsWire

HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wa...

4 months ago - GlobeNewsWire

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be steppin...

4 months ago - GlobeNewsWire

Aravive is drugging the GAS6-AXL pathway to develop new medicines across several cancer indications. Early clinical data has established safety for the company's lead drug candidate, AVB-500, and early ...

4 months ago - Seeking Alpha

HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian...

6 months ago - GlobeNewsWire

HOUSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financial ...

6 months ago - GlobeNewsWire

Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Pla...

8 months ago - GlobeNewsWire

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran ...

8 months ago - GlobeNewsWire

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and co...

8 months ago - GlobeNewsWire

Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Pl...

8 months ago - GlobeNewsWire

HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financia...

9 months ago - GlobeNewsWire

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and con...

9 months ago - GlobeNewsWire

Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500  in Platinum Resistant Ovarian Cancer

9 months ago - GlobeNewsWire

HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases,...

10 months ago - GlobeNewsWire

Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings and capital...

Other stocks mentioned: AHCO, CGIX, GNUS, NOVA, PAYS, RMBL
10 months ago - 24/7 Wall Street

In the latest trading session, Aravive (ARAV) closed at $14.11, marking a -1.47% move from the previous day.

10 months ago - Zacks Investment Research

Aravive (ARAV) closed at $13.55 in the latest trading session, marking a -0.88% move from the prior day.

11 months ago - Zacks Investment Research

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.

1 year ago - Zacks Investment Research

HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with lead...

1 year ago - GlobeNewsWire

Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.

1 year ago - Zacks Investment Research

Is (ARAV) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Aravive.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for April 20th

Other stocks mentioned: BCRX, CYAD, MRSN
1 year ago - Zacks Investment Research

Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman

1 year ago - GlobeNewsWire

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase...

1 year ago - GlobeNewsWire

Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline

1 year ago - GlobeNewsWire

HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a clini...

1 year ago - GlobeNewsWire

Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threateni...

1 year ago - GlobeNewsWire

HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threateni...

1 year ago - GlobeNewsWire

Aravive Inc. (NASDAQ: ARAV) shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.

1 year ago - 24/7 Wall Street

Aravive stock doubled in value Wednesday after the biotech company delivered bullish test results for a high-dose ovarian cancer treatment vs. a lower dose of the same experimental medicine.

1 year ago - Investors Business Daily

Shares of Aravive ARAV, +3.40% are up 270% in premarket trading Wednesday after the Houston-based biotech reported positive data from an early-stage clinical trial.

1 year ago - Market Watch

Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

1 year ago - Seeking Alpha

About ARAV

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to blo... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 2014
CEO
Gail McIntyre
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ARAV
Full Company Profile

Financial Performance

In 2020, Aravive's revenue was $5.69 million, an increase of 19.61% compared to the previous year's $4.75 million. Losses were -$30.54 million, 67.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Aravive stock is "Buy." The 12-month stock price forecast is 22.50, which is an increase of 336.89% from the latest price.

Price Target
$22.50
(336.89% upside)
Analyst Consensus: Buy